Pantop%252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520ds

# Pantoprazole ## Overview Pantoprazole is a proton pump inhibitor (PPI) that reduces gastric acid production. ## Primary Indications * Healing of erosive esophagitis associated with gastroesophageal reflux disease (GERD). * Maintenance of healing of erosive esophagitis. * Treatment of pathological hypersecretory conditions, including Zollinger-Ellison syndrome. ## Adult Dosing * **Erosive esophagitis:** 40 mg orally or intravenously once daily for up to 8 weeks. A 4-week course may be sufficient for some patients. * **Maintenance of healing:** 40 mg orally once daily. For some patients, 20 mg orally once daily may suffice. * **Pathological hypersecretory conditions:** Start with 40 mg orally or intravenously twice daily. Doses may be increased as needed. Doses up to 240 mg daily have been administered intravenously. ## Pediatric Dosing Dosing in pediatric patients varies significantly by age and indication. Consult specific pediatric guidelines or product information. * **GERD (ages 5 to 16 years):** * **Erosive esophagitis:** 20 mg orally once daily for up to 8 weeks. * **Maintenance of healing:** 20 mg orally once daily. * **Symptomatic GERD:** 40 mg orally once daily or 20 mg orally once daily for up to 4 weeks. ## Dose Adjustments No dose adjustment is generally required for hepatic or renal impairment. ## Contraindications * Known hypersensitivity to pantoprazole or any component of the formulation. ## Adverse Effects Common adverse effects include diarrhea, headache, dizziness, and abdominal pain. Long-term use of PPIs may be associated with an increased risk of *Clostridium difficile*-associated diarrhea, bone fractures (hip, wrist, spine), and vitamin B12 deficiency. Hypomagnesemia has also been reported. ## Key Drug Interactions * **Drugs requiring gastric pH for absorption:** Pantoprazole can decrease absorption of drugs like ketoconazole, itraconazole, posaconazole, iron salts, and vitamin B12. * **Methotrexate:** Concurrent use with PPIs may increase methotrexate levels, potentially leading to toxicity. * **CYP2C19 Substrates:** Pantoprazole may inhibit CYP2C19, potentially increasing levels of drugs metabolized by this enzyme (e.g., clopidogrel). ## Monitoring * Monitor for signs and symptoms of *Clostridium difficile*-associated diarrhea. * Consider monitoring magnesium levels, especially in patients on long-term therapy or concomitant diuretic use. * Assess for bone fracture risk in patients with risk factors. * Evaluate for signs of vitamin B12 deficiency with prolonged use. ## Clinical Pearls * For IV administration, reconstitute and further dilute. Do not administer with other medications through the same intravenous line. * Pantoprazole is generally considered less likely to inhibit CYP2C19 compared to omeprazole or esomeprazole, but caution is still advised. * Short-term use is recommended for GERD symptoms. For long-term therapy, regularly reassess the need for continued treatment. *** *This information is intended for healthcare professionals. Always consult the most current prescribing information and local guidelines before making any clinical decisions.*